Free Trial

Femasys Q4 2022 Earnings Report

Femasys logo
$1.09 -0.01 (-0.91%)
(As of 12/20/2024 05:31 PM ET)

Femasys EPS Results

Actual EPS
-$0.24
Consensus EPS
-$0.26
Beat/Miss
Beat by +$0.02
One Year Ago EPS
N/A

Femasys Revenue Results

Actual Revenue
$0.23 million
Expected Revenue
$0.40 million
Beat/Miss
Missed by -$170.00 thousand
YoY Revenue Growth
N/A

Femasys Announcement Details

Quarter
Q4 2022
Time
N/A

Conference Call Resources

Could This Tiny Device Help You Make an Extra $30k a Year? (Ad)

I believe it’s going to power Elon Musk’s next AI revolution… A revolution he believes will be worth more than $9 trillion. That’s nearly 10 times more money than the market caps of Tesla… SpaceX… PayPal… Neuralink… and X… COMBINED.

Click here to see the details because I believe a lot of people will get rich.

Femasys Earnings Headlines

Femasys’s Strategic Partnerships and Market Expansion Drive Buy Rating
Crypto’s hidden gem + greatest crypto bull run in history = $$$?
You don’t actually want to buy Bitcoin this time around. That’s because there’s a better way to take advantage of this new bull market… One market expert calls it Crypto’s Hidden Gem And it’s a new way that has given folks like you and me the chance to see bigger and faster moves than the traditional way of buying Bitcoin… That means if you’ve stayed away from Bitcoin and crypto because it's confusing or seems risky… This is a much safer and better approach to ride this years’ crypto bull run. Because believe it or not… The 2024 crypto bull run is one you DON’T want to miss.
The Latest Analyst Ratings For Femasys
Femasys announces peer-reviewed data from FemaSeed ITI in JGRM
See More Femasys Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Femasys? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Femasys and other key companies, straight to your email.

About Femasys

Femasys (NASDAQ:FEMY), a biomedical company, develops therapeutic and diagnostic solutions to address unmet women healthcare needs worldwide. The company provides FemVue saline-air device, a contrast-generating product in the United States, Canada, Japan, and Hong Kong; FemCath, a cornual balloon catheter, a single intrauterine directional delivery product that allows for selective evaluation of an individual fallopian tube; and FemCerv, a biopsy device for endocervical curettage, which can be used to sample cervical cells and tissue circumferentially with sample containment within the device to minimize contamination. It also develops permanent birth control solutions, such as FemBloc and FemChec; FemaSeed, an artificial insemination solution; and FemEMB, a product candidate for endometrial sampling in support of uterine cancer detection testing. The company offers its products to reproductive endocrinologists for infertility products, obstetrics-gynecological physicians, related healthcare professionals, and women's healthcare provider organizations. Femasys Inc. was incorporated in 2004 and is headquartered in Suwanee, Georgia.

View Femasys Profile

More Earnings Resources from MarketBeat

Upcoming Earnings